Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 109.76B +15.1% |
| Revenue (ttm) | 2.41B +39.0% |
| Net Income | 174.57M |
| EPS | 0.75 |
| Shares Out | 239.02M |
| PE Ratio | 613.61 |
| Forward PE | 253.55 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 526,657 |
| Open | 465.80 |
| Previous Close | 463.80 |
| Day's Range | 449.40 - 466.00 |
| 52-Week Range | 339.60 - 562.50 |
| Beta | 0.10 |
| Analysts | Strong Buy |
| Price Target | 617.60 (+34.5%) |
| Est. Earnings | Nov 18, 2026 |
About HKG:6990
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally. The company’s product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a... [Read more]
Financial Performance
In 2025, HKG:6990's revenue was 2.06 billion, an increase of 6.46% compared to the previous year's 1.93 billion. Losses were -381.97 million, 43.2% more than in 2024.
Financial numbers in CNY Financial StatementsAnalyst Summary
According to 21 analysts, the average rating for 6990 stock is "Strong Buy." The 12-month stock price target is $617.60, which is an increase of 34.50% from the latest price.
News
Sichuan Kelun-Biotech Biopharmaceutical Earnings Call Transcript: H1 2026
Revenue reached RMB 978 million in H1 2026, with commercialization revenue more than doubling year-on-year. Strong clinical data and expanded reimbursement drove growth, while R&D investment rose 25.7%. Break-even is expected soon as new indications and global partnerships advance.
Sichuan Kelun-Biotech Biopharmaceutical Earnings release: H1 2026
Sichuan Kelun-Biotech Biopharmaceutical released its H1 2026 earnings on August 17, 2026, summarizing the period's financial results.
Sichuan Kelun-Biotech Biopharmaceutical Slides: H1 2026
Sichuan Kelun-Biotech Biopharmaceutical has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 17, 2026.
Sichuan Kelun-Biotech Biopharmaceutical Quarterly report: H1 2026
Sichuan Kelun-Biotech Biopharmaceutical has published its H1 2026 quarterly earnings report on August 17, 2026.
Sichuan Kelun-Biotech Biopharmaceutical Earnings Call Transcript: H2 2025
Revenue grew 6.5% to CNY 2.06 billion in 2025, driven by new product launches and expanded NRDL coverage. Gross margin rose 16.1%, but net loss increased due to higher commercialization expenses. Strong cash reserves and global partnerships support future growth.
Sichuan Kelun-Biotech Biopharmaceutical Earnings release: H2 2025
Sichuan Kelun-Biotech Biopharmaceutical released its H2 2025 earnings on March 23, 2026, summarizing the period's financial results.
Sichuan Kelun-Biotech Biopharmaceutical Slides: H2 2025
Sichuan Kelun-Biotech Biopharmaceutical has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 23, 2026.
Sichuan Kelun-Biotech Biopharmaceutical Annual report: H2 2025
Sichuan Kelun-Biotech Biopharmaceutical has published its H2 2025 annual report on March 23, 2026.
Sichuan Kelun-Biotech Biopharmaceutical Transcript: 44th Annual J.P. Morgan Healthcare Conference
A leading biopharma presented its robust pipeline, including four approved oncology products and innovative ADCs, with strong clinical results and global partnerships. Strategic priorities include expanding indications, advancing novel drug conjugates, and growing international presence.
Crescent, Kelun-Biotech Sign Oncology Deal; Crescent To Raise $185 Mln; Stock Up
(RTTNews) - Crescent Biopharma, Inc. (CBIO), on Thursday announced an exclusive partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to develop and commercialize oncology therapeutics, i...